Articles tagged "HLA antigens"

2020 American Transplant Congress
A Multicenter Analysis of the Proportion and Pattern of Unexplained HLA Antibodies in Kidney Recipients without a History of Sensitization
J. Lan¹, J. S. Gill¹, H. M. Gebel², R. A. Bray², R. Liwski³, A. Vinson⁴, A. Greenshields³, S. Dobrer⁵, O. Gunther⁵, K. Sherwood⁵, F. H. Claas⁶, S. Heidt⁶, G. Karahan⁶, J. Gill⁷, M. Gill¹, U. Varyani¹, P. Jindal¹, P. Keown⁵
¹Medicine, Division of Nephrology, University of British Columbia, Vancouver, BC, Canada, ²Pathology, Emory University, Atlanta, GA, ³Pathology, Dalhousie University, Halifax, NS, Canada, ⁴Nephrology, Dalhousie University, Halifax, NS, Canada, ⁵Pathology, University of British Columbia, Vancouver, BC, Canada, ⁶Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands, ⁷Nephrology, Emory University, Atlanta, GA
*Purpose: Previous studies report a high prevalence of unexplained antibody reactivities on the single antigen bead (SAB) test. In a contemporary multicenter cohort of non-sensitized…
2020 American Transplant Congress
A New Diagnostic Approach to HLA Testing in Kidney Transplant Patients Using Renal Epithelial Cells
M. Herrmann¹, C. Bach², K. X. Knaup¹, M. Schiffer¹, B. Spriewald², M. S. Wiesener¹
¹Nephrology and Hypertension, University Hospital Erlangen, Erlangen, Germany, ²Haematology and Oncology, University Hospital Erlangen, Erlangen, Germany
*Purpose: In this study we present a new diagnostic approach to HLA typing in kidney transplant recipients using cultured renal tubular cells from urine samples…
2020 American Transplant Congress
Rare HLA DRB1*10-DQB1*06 Linkage Disequilibrium: A Case Study That Emphasizes the Need of Having an HLA Toolbox
S. Dionne, L. Santiago, S. Shetty
VRL-Eurofins, Centennial, CO
*Purpose: This case study highlights the need to use different tools to derive and validate HLA typing results especially in instances of rare typing.*Methods: Low/intermediate…
2020 American Transplant Congress
HLA-DQ Plays an Important Role in Graft Survival in African American Transplant Recipients
L. M. Rebellato¹, W. Irish², D. Leeser², J. Tuttle², C. E. Haisch²
¹Pathology, The Brody School of Medicine at ECU, Greenville, NC, ²Surgery, The Brody School of Medicine at ECU, Greenville, NC
*Purpose: Our kidney transplant (KTx) program serves a medically underserved and racially diverse area of a southern state. The purpose of this study was to…
2020 American Transplant Congress
Cardiac Transplantation is Accompanied by Major T and NK Cell Alterations within the First 24 Hours
J. Iske¹, B. Wiegmann², K. Ludwig¹, N. Ledwoch¹, E. Chichelnitskiy¹, J. F. Kühne¹, A. Hitz¹, R. Bellmàs-Sanz¹, K. Daemen¹, J. Keil¹, F. Ius², S. Rochas², A. Knoefel², A. Haverich², G. Warnecke², C. S. Falk¹
¹Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany, ²Division of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
*Purpose: Allogeneic heart transplantation (HTx) displays the only curative approach for terminal heart insufficiency while acute allograft rejection remains a major complication. However, early kinetics…
2020 American Transplant Congress
Risk Epitope Mismatch Does Not Predict Short Term Heart Transplant Outcomes
Y. Moayedi¹, J. McCaughan², E. Henricksen³, B. Mueller⁴, S. Fan⁴, H. J. Ross¹, K. Khush⁵, B. M. Zhang⁶, J. Teuteberg⁵
¹Cardiology, Ted Rogers Centre for Heart Research, University Health Network, University of Toronto, Toronto, ON, Canada, ²HLA Lab, Belfast Trust, Belfast, Ireland, ³Pharmacy, Stanford Healthcare, Stanford, CA, ⁴Computational Program TRCHR, Ted Rogers Centre for Heart Research, University Health Network, University of Toronto, Toronto, ON, Canada, ⁵Cardiology, Stanford University, Stanford, CA, ⁶HLA Lab, Stanford University, Stanford, CA
*Purpose: Heart transplantation (HT) remains the gold standard treatment for end-stage heart failure. Despite significant improvements in short-term outcomes, the median survival after heart transplantation…
2020 American Transplant Congress
Low HLA Class I Epitope Mismatch Associated with Improved Pancreas Graft Survival in Simultaneous Pancreas-Kidney Transplantation
J. M. Ladowski, M. Romine, D. Kloda, C. Young, J. Locke, V. Hauptfeld-Dolejsek, J. Houp
University of Alabama-Birmingham, Birmingham, AL
*Purpose: Antibody-mediated rejection remains the principal cause of allotransplant graft failure. Human leukocyte antigen (HLA) matching between donor and recipients significantly reduces the risk of…
2020 American Transplant Congress
HLA Cw12 in Kidney Transplant Recipients is a Novel Risk Factor for the Development of Post-Transplantation Diabetes: A Single-Centre Retrospective Study
N. Phagura¹, A. Culliford², F. Evison³, S. Gallier³, J. Nath², D. Briggs⁴, A. Sharif²
¹College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ²Department of Nephrology and Transplantation, University Hospitals Birmingham, Birmingham, United Kingdom, ³Department of Health Informatics, University Hospitals Birmingham, Birmingham, United Kingdom, ⁴H&I Birmingham, NHS Blood and Transplant, Birmingham, Birmingham, United Kingdom
*Purpose: Counselling kidney transplant candidates for their personalised risk of developing post-transplantation diabetes mellitus (PTDM) requires an understanding of risk factors. While some risk factors…
2020 American Transplant Congress
The Clinical Significance of C1q+ Antibodies in Pediatric Kidney Transplant Recipients
N. Hayde¹, S. Solomon², A. Colovai¹
¹Montefiore Medical Center, Bronx, NY, ²Westchester Medical Center, Valhalla, NY
*Purpose: To evaluate the impact of denovo DSA (C1q+ vs C1q-) on graft outcomes in pediatric kidney transplant recipients.*Methods: Children transplanted between 2009 and 2016…
2020 American Transplant Congress
Identification of the dnDSA Inducing HLA Mismatches Across Multiple Renal Transplant Centers: A 3-Year Longitudinal Analysis of >11,000 HLA Mismatches in 2271 Patients
J. M. Brennan¹, M. D. Stegall², C. A. Schinstock², R. L. Heilman³, L. M. Rebellato⁴, M. D. Samaniego-Picota⁵, D. Lesser⁴, M. J. Ghandi², J. L. Beaumont¹, M. J. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Phoenix, AZ, ⁴East Carolina University, Greenville, NC, ⁵Henry Ford Transplant Institute, Detroit, MI
*Purpose: The presence of a mismatch (MM) between donor and recipient HLA does not always lead to the patient developing a de novo donor-specific anti-HLA…